Zhejiang Xinguang Pharmaceutical Co., Ltd. (SHE:300519)
15.01
-0.54 (-3.47%)
May 21, 2026, 3:04 PM CST
SHE:300519 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 260.35 | 265.13 | 267.54 | 270.28 | 351.37 | 320.77 |
Other Revenue | 0.23 | 0.23 | 0.12 | 0.11 | 0.12 | 0.11 |
| 260.58 | 265.36 | 267.66 | 270.4 | 351.49 | 320.88 | |
Revenue Growth (YoY) | 0.08% | -0.86% | -1.01% | -23.07% | 9.54% | 13.35% |
Cost of Revenue | 152.54 | 163.14 | 177.89 | 160.03 | 169.81 | 145.29 |
Gross Profit | 108.04 | 102.22 | 89.77 | 110.37 | 181.68 | 175.58 |
Selling, General & Admin | 35.98 | 38.26 | 41.5 | 43.64 | 50.61 | 49.27 |
Research & Development | 11.9 | 13.35 | 12.62 | 15.13 | 15.55 | 13.52 |
Other Operating Expenses | 4.41 | 4.35 | 3.5 | 3.43 | 4.26 | 4.22 |
Operating Expenses | 52.14 | 55.76 | 57.74 | 61.51 | 70.86 | 66.85 |
Operating Income | 55.9 | 46.46 | 32.03 | 48.87 | 110.82 | 108.73 |
Interest & Investment Income | 9.65 | 16.76 | 23.55 | 22.98 | 14.09 | 23.03 |
Other Non Operating Income (Expenses) | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 | -0.01 |
EBT Excluding Unusual Items | 65.54 | 63.2 | 55.57 | 71.83 | 124.9 | 131.74 |
Gain (Loss) on Sale of Assets | - | -0 | -0.07 | -0.29 | - | -0.71 |
Asset Writedown | 0.16 | -0.04 | -0.01 | 0.02 | 0 | -0.02 |
Other Unusual Items | 0.04 | 0.27 | 1.51 | 1.6 | 0.7 | 0.95 |
Pretax Income | 65.74 | 63.43 | 57.01 | 73.16 | 125.6 | 131.96 |
Income Tax Expense | 9.7 | 9.22 | 6.62 | 8.8 | 16.78 | 17.68 |
Net Income | 56.04 | 54.21 | 50.39 | 64.36 | 108.82 | 114.28 |
Net Income to Common | 56.04 | 54.21 | 50.39 | 64.36 | 108.82 | 114.28 |
Net Income Growth | 7.56% | 7.58% | -21.70% | -40.86% | -4.78% | 15.46% |
Shares Outstanding (Basic) | 160 | 159 | 163 | 161 | 160 | 161 |
Shares Outstanding (Diluted) | 160 | 159 | 163 | 161 | 160 | 161 |
Shares Change (YoY) | -1.81% | -1.91% | 1.03% | 0.54% | -0.58% | 0.83% |
EPS (Basic) | 0.35 | 0.34 | 0.31 | 0.40 | 0.68 | 0.71 |
EPS (Diluted) | 0.35 | 0.34 | 0.31 | 0.40 | 0.68 | 0.71 |
EPS Growth | 9.54% | 9.68% | -22.50% | -41.18% | -4.23% | 14.52% |
Free Cash Flow | 76.21 | 65.45 | 48.23 | 37.3 | 109.78 | 127.64 |
Free Cash Flow Per Share | 0.48 | 0.41 | 0.30 | 0.23 | 0.69 | 0.79 |
Dividend Per Share | 0.300 | 0.300 | 0.300 | 0.400 | 0.500 | 0.600 |
Dividend Growth | - | - | -25.00% | -20.00% | -16.67% | - |
Gross Margin | 41.46% | 38.52% | 33.54% | 40.82% | 51.69% | 54.72% |
Operating Margin | 21.45% | 17.51% | 11.97% | 18.07% | 31.53% | 33.88% |
Profit Margin | 21.50% | 20.43% | 18.83% | 23.80% | 30.96% | 35.62% |
Free Cash Flow Margin | 29.25% | 24.66% | 18.02% | 13.80% | 31.23% | 39.78% |
EBITDA | 70.59 | 61.2 | 46.97 | 63.64 | 124.88 | 121.59 |
EBITDA Margin | 27.09% | 23.06% | 17.55% | 23.54% | 35.53% | 37.89% |
D&A For EBITDA | 14.69 | 14.74 | 14.93 | 14.77 | 14.05 | 12.86 |
EBIT | 55.9 | 46.46 | 32.03 | 48.87 | 110.82 | 108.73 |
EBIT Margin | 21.45% | 17.51% | 11.97% | 18.07% | 31.53% | 33.88% |
Effective Tax Rate | 14.76% | 14.53% | 11.61% | 12.03% | 13.36% | 13.40% |
Revenue as Reported | 260.58 | 265.36 | 267.66 | 270.4 | 351.49 | 320.88 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.